Interferon tau (IFNT) from the ovine conceptus has paracrine actions on the endometrium that alter release of prostaglandin F 2alpha (PGF) and protect the corpus luteum (CL). Antiviral activity in uterine vein blood and expression of interferonstimulated genes (ISGs) in CL is greater in pregnant than in nonpregnant ewes. We hypothesized that IFNT contributes to antiviral activity in uterine vein blood and has endocrine actions on the CL. Preadsorption of IFNT with antiserum against recombinant ovine (ro) IFNT revealed that antiviral activity in uterine vein blood from pregnant ewes was mediated by IFNT.
Interferon tau (IFNT) from the ovine conceptus has paracrine actions on the endometrium that alter release of prostaglandin F 2alpha (PGF) and protect the corpus luteum (CL). Antiviral activity in uterine vein blood and expression of interferonstimulated genes (ISGs) in CL is greater in pregnant than in nonpregnant ewes. We hypothesized that IFNT contributes to antiviral activity in uterine vein blood and has endocrine actions on the CL. Preadsorption of IFNT with antiserum against recombinant ovine (ro) IFNT revealed that antiviral activity in uterine vein blood from pregnant ewes was mediated by IFNT. Endocrine actions of IFNT were examined after infusing either roIFNT or bovine serum albumin (BSA; 200 lg/24 h; miniosmotic pump) into the uterine vein of nonpregnant ewes from Day 10 to Day 11 postestrus. The abundance of ISG15 mRNA and protein was greater in CL (P , 0.05) from ewes receiving 24-h roIFNT infusion compared to that from ewes receiving 24-h BSA infusion. Injection of PGF at 12 h following insertion of mini-osmotic pumps resulted in a decline in serum progesterone concentrations 6 through 12 h later in BSA-infused ewes; however, in roIFNT-infused ewes, a similar decline in progesterone concentrations at 6 h was followed by recovery to control values at 12 h. Ewes then received infusions (200 lg/day) of either roIFNT or BSA for 7 days beginning on Day 10 of the estrous cycle. All BSA-infused ewes returned to estrus by Day 19 , whereas 80% of roIFNT-infused ewes maintained lutealphase concentrations of progesterone through Day 32. In conclusion, IFNT is released from the uterus into the uterine vein and acts through an endocrine mechanism to induce ISGs in the CL and delay luteolysis.
INTRODUCTION
The major protein product of cultured Day 13 ovine conceptuses is 17 000 M r and was initially referred to as protein X [1] . This protein, secreted by the elongating conceptus trophectoderm beginning on Days 10-12, was renamed ovine trophoblast protein-1 and, later, interferon tau (IFNT) [2] [3] [4] [5] [6] . Peak production and secretion of IFNT from the ovine conceptus occurs between Days 15 and 17 of pregnancy [6] [7] [8] . Twice-daily infusions or injections of IFNT [9] or recombinant ovine (ro) IFNT [10, 11] into the uterus of sheep for 2-8 days extends luteal life span to 22-27 days postestrus. This transient extension of the estrous cycle was thought to be regulated by paracrine actions of IFNT on the endometrium [7] . IFNT abrogates transcription of estrogen receptor alpha (ESR1) [12, 13] and, consequently oxytocin receptor (OXTR) [13, 14] in the endometrium. Decreased transcription of the OXTR likely results from the decrease in ESR1 caused by IFNT, because OXTR is not directly regulated by IFNT [15] . Attenuating ESR1 and OXTR expression in the endometrium prevents the luteolytic mechanism in ewes [16, 17] and cows [18, 19] responsible for secretion of luteolytic pulses of prostaglandin F 2alpha (PGF).
Type I receptors (IFNAR1 and IFNAR2) are expressed in all cells of the body to mediate antiviral responses. IFNAR1 and IFNAR2 are also localized in ovine uterine epithelial and stromal cells and mediate maternal responses to conceptusderived IFNT [20] . Some of the IFN-stimulated genes (ISGs) that are up-regulated in the ruminant uterus during early pregnancy include 2 0 ,5 0 -oligoadenylate synthetase (OAS) [21] [22] [23] , myxovirus (influenza virus) resistance 1 (MX1) [24] , and IFN-stimulated gene 15 (ISG15) [25] [26] [27] . Until recently, conceptus-derived IFNT was thought to act exclusively within the uterus. However, ISGs are expressed in peripheral blood mononuclear cells after initial IFNT signaling in pregnant ruminants [28] [29] [30] . Pregnancy and IFNT also induce ISGs within the corpus luteum (CL) [31] . Chen et al. [14] reported that luteal expression of OXTR was not different between ewes treated with intrauterine roIFNT and cyclic ewes, but that PGF synthase (PGFS) expression decreased in roIFNT-treated ewes. These results are interpreted to mean that prostaglandin synthesis in the CL of roIFNT-treated ewes may be inhibited as a mechanism for maintaining production of progesterone by CL during early pregnancy. This is consistent with previous reports of an intraluteal role for prostaglandins in the luteolytic process [32, 33] .
PGF is released into the uterine vein and reaches the ovarian artery through countercurrent exchange (for review, see [34] ) to induce luteolysis in cyclic cows. Pregnant cows have diminished endometrial production and release of PGF [34] ; however, some PGF can still reach the ovary during early pregnancy. Pregnant and cyclic ewes have very different patterns of secretion of PGF into the utero-ovarian vein between Days 14 and 16 of the estrous cycle [16, 35] . Whereas peak production of PGF occurs on Days 15-16 regardless of pregnancy status, cyclic ewes secrete PGF in a pulsatile fashion, which is absent in pregnant ewes that have a protracted increase in concentrations of PGF in utero-ovarian vein blood [17, 36] . More PGF is secreted by the uterus into the uterine veins of Day 13 pregnant ewes than in cyclic ewes [37] . Also, the presence of PGF in the uterine vein during pregnancy may necessitate a self-preservation mechanism for the CL to make hydroxy-prostaglandin dehydrogenase (HPGD). Silva et al. [38] reported a significant increase in HPGD mRNA and enzyme activity in Day 13 CL from pregnant ewes compared to Day 13 nonpregnant ewes.
The first report that IFN exits the uterus was obtained by means of an antiviral assay using type I IFN as a control [31] . Plasma samples from the uterine vein of Day 15 pregnant ewes had antiviral activity that was equivalent to 250 lg/day (500-1000 U/ml) of type I IFN [31] . These results support the idea that type I IFN, presumably IFNT from ruminant conceptuses, enters the peripheral circulation via the uterine vein to exert endocrine effects on extrauterine tissues, such as blood cells and the CL. We hypothesized that IFNT maintains production of progesterone and life span of the CL through direct actions on the CL. In the present experiments, two animal models were used to test this hypothesis. One model entailed examination of ISGs in endometrium and CL from Day 15 cyclic or pregnant ewes. The other model examined similar endpoints, including serum progesterone concentration, but circumvented direct action of IFNT on the endometrium through installation of mini-osmotic pumps with 24-h or 7-day endocrine delivery of roIFNT into the uterine vein starting on Day 10 postestrus.
MATERIALS AND METHODS

Animals
All experimental procedures using animals were reviewed and approved by the Colorado State University Animal Care and Use Committee. Estrus was synchronized in mature, white-faced, western range ewes during the midluteal phase with two injections of PGF (5 mg i.m.; Lutalyse; Pfizer) administered 4 h apart. Upon detection of estrus (Day 0) with a caudaepididyectomized ram, ewes were placed into experimental groups.
Preadsorption of IFNT and Antiviral Assay
Uterine vein plasma and serum samples from ewes on Day 15 of pregnancy were preadsorbed with a 1:10 molar excess of rabbit anti-roIFNT antibody (1 mg/ml) [39] or normal rabbit serum for 24 h at 48C. The concentration of antibody used in preadsorption was based on our previous estimates of 500-1000 IU (5-10 ng) of IFNT per milliliter of uterine vein blood [31] . The preadsorbed serum and plasma were centrifuged at 16 000 3 g for 20 min and the supernatant subjected to an antiviral assay. Uterine vein plasma and serum from Day 15 pregnant and nonpregnant ewes were analyzed in the assay to provide positive and negative controls, respectively.
The antiviral assay was performed as previously described [31, 40] with a few modifications. Madin-Darby bovine kidney (MDBK) cells were plated in Dulbecco minimal essential medium with glucose (4.5 g/L) supplemented with 1% L-glutamine, 5% fetal bovine serum (v/v; Gemini Bioproducts), and 1% penicillin/streptomycin/amphotericin B solution (Sigma-Aldrich) at 3 3 10 cells/well in 96-well plates and cultured to confluence for 24 h. Ovine plasma or serum was added to cells using 1:4 to 1:32 serial dilutions and cultured for 24 h at 378C (95% air/5% CO 2 ). Serial twofold dilutions of Universal Type 1 IFN (Biomedical Laboratories) starting at 1000 U/ml were used to create IFN standards. Cells were challenged with Indiana laboratory strain of vesicular stomatitis virus (50-100 PFU) for 42 h. Cells cultured in the absence of IFN were either challenged with vesicular stomatitis virus or not challenged to develop controls. Plates were stained with 0.5% crystal violet in 70% methanol for 1 h, and optical density of the remaining monolayer was measured by absorbance at 540 nm in a spectrophotometer and adjusted (subtraction) for blanks (viral control wells). The antiviral index was calculated by dividing the optical density of the experimental wells with the optical density of the untreated control wells. Antiviral units were determined through comparing antiviral activity of the experimental sample with antiviral activity in the dilutions of IFN standards.
Luteal Gene Expression in Day 15 Pregnant and Cyclic Ewes
Six cyclic ewes were bred to an intact ram on the day of estrus (Day 0), and six ewes mated to a caudaepididyectomized ram were used as controls. Fifteen days after onset of estrus, jugular venous blood samples were collected using Vacutainers (BD) at necropsy. Ewes were anesthetized with sodium pentobarbital (i.v.; 20 mg/kg). A midventral laparotomy was performed to expose the reproductive tract, and uterine venous and ovarian arterial blood samples were collected. All blood samples were held at 48C for 12 h to clot before serum was separated via centrifugation (30 min, 2500 3 g, 48C) and then stored at À208C until analyzed. Luteal, endometrial, and liver samples were collected, snapfrozen in liquid nitrogen, and stored (À808C) until analyzed for mRNAs and proteins. Pregnancy was confirmed by the presence of elongated conceptuses.
Development of a Method for Endocrine Delivery of roIFNT to the Ovary
Recombinant ovine IFNT with a specific activity of 10 8 U/mg was produced and purified as previously described [41] . Ewes were anesthetized with sodium pentobarbital (Sigma) and maintained on isofluorane (Minrad, Inc.) on Day 10 of the estrous cycle. The first group of ewes was treated with a single ovarian arterial injection containing 200 lg (1 lg/ll) of BSA (n ¼ 2) or roIFNT (n ¼ 2) over 60 sec. The dose of 200 lg of roIFNT was chosen based on previous antiviral assay in our laboratory [31] , suggesting release of IFNT in the uterine vein of 500-1000 U or 5-10 ng/ml. Assuming that uterine blood flow ipsilateral to the CL is approximately 13.5 ml/min [42] and using the 10 ng/ml estimate, this equates to 67.5 ng/ml or approximately 194 lg/24 h. This concentration of IFNT also was identical to that found during studies in which 2 3 10 7 U (200 lg) was infused into the uterine lumen [43] and abrogated development of luteolytic mechanisms in the endometrium. The CLs were removed 12 h later at necropsy to allow time for up-regulation of ISGs in response to roIFNT.
FIG. 1. Uterine vein blood antiviral indices increase during pregnancy
and are primarily the result of IFNT. Uterine vein serum had greater antiviral activity on Day 15 of pregnancy (P; n ¼ 5 ewes) compared to the estrous cycle (NP; n ¼ 3 ewes), which was similar to previous reports when examining uterine vein plasma [31] . Preadsorption of uterine vein plasma collected on Day 15 of pregnancy with antibody against roIFNT (P-PA; n ¼ 2 ewes) blocked most of the antiviral activity found in uterine vein blood preadsorbed with normal rabbit serum (NRS; n ¼ 2 ewes). Similar loss in antiviral activity was observed when preadsorbing uterine vein serum collected on Day 15 of pregnancy with antiserum against roIFNT (not shown). Indices reflect the mean 6 SEM. Means with different lowercase letters within experiment (NP vs. P, P-NRS vs. P-PA) differ significantly (P , 0.05).
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A second method of systemic delivery of roIFNT or BSA was into the uterine vein. Mini-osmotic pumps (24 h, 200 ll pump, 2001D, 8.0 ll/h; Alzet #2001D; Durect Corporation) preloaded with roIFNT (200 lg) and connected to a catheter (inner diameter, 0.94 mm) were surgically inserted into the uterine vein upstream of the close apposition with the ovarian artery on the side ipsilateral to the CL (see Fig. 2 ). The catheter and pump were anchored to the reproductive tract with cyanoacrylate glue (Super Glue). The mini-osmotic pumps release contents over 24 h. In ewes that had a CL on each ovary, the CL was noted as being ipsilateral or contralateral to the side of the reproductive tract on which the pump was placed. The CLs were collected via necropsy at 24 h after installation of pumps. To ensure that mini-osmotic pumps were delivering roIFNT per specifications, two additional ewes received miniosmotic pumps that were collected at necropsy 12 h postsurgery. Pumps designed for 24-h delivery were inspected at 12 h following surgical installation and were found to contain approximately 50% of the initial volume, indicating that they were operating properly. Detection of CL ISG15 mRNA by using semiquantitative real-time PCR [31] was used as a marker for IFNT action.
Short-Term (24-h) Uterine Vein Infusion of roIFNT and (12-h) PGF Challenge In Vivo
The 24-h mini-osmotic pumps containing 200 lg of BSA (n ¼ 12) or roIFNT (n ¼ 12) were surgically implanted. One-half of the ewes in the BSA and roIFNT groups (n ¼ 6 each) received a single injection of Lutalyse (5 mg i.m.) 12 h after surgery. The timing of Lutalyse injection was selected to allow up-regulation of ISGs in the CL following installation of mini-osmotic pumps. Six additional ewes underwent sham surgeries in which capped catheters were inserted into uterine veins (pumps were not inserted) to serve as procedural controls. Jugular vein blood samples were collected at 0, 12, 14, 16, 18, 20, 22, and 24 h after surgery for subsequent serum progesterone radioimmunoassay. All ewes were killed 24 h after surgery. Luteal, endometrial, and uterine venous blood samples were collected at necropsy as described previously [31] .
Long-Term (7-d) Infusion of roIFNT into the Uterine Vein
Mini-osmotic pumps engineered for 7-day delivery (2 ml, 10 ll/h; Alzet 2ML1-AA) were loaded with 1400 lg (200 lg/day) of BSA (n ¼ 6) or roIFNT (n ¼ 6) and surgically installed on Day 10 of the estrous cycle as previously described. The CLs were marked with charcoal at time of surgery to allow identification at necropsy. Jugular vein blood samples were collected once daily between Days 10 and 13 after onset of estrus. More frequent blood samples were collected at 12-h intervals between Days 14 and 17 to capture the decline in serum progesterone following endogenous release of PGF. Samples from each ewe were pooled within day for analysis of serum progesterone concentrations. Caudaepididyectomized rams were utilized twice daily to detect estrus in ewes from Day 13 to Day 17 after onset of estrus. Ewes were killed upon detection of estrus or on Day 32 postestrus (if they did not exhibit estrous behavior sooner), and tissues were collected as previously described.
Semiquantitative Real-Time PCR Analysis
Total RNA was extracted from luteal and endometrial samples using TRIzol Reagent (Invitrogen) protocol. RNase-free DNase (Qiagen) and RNeasy MinElute Cleanup Kits (Qiagen) were used to digest DNA and purify RNA. Quantification of RNA was performed using a NanoDrop (NanoDrop Technologies, Inc.). Single-stranded cDNA was synthesized from 1 lg of RNA using the iScript cDNA Synthesis Kit (Bio-Rad). This cDNA was used as a template for semiquantitative real-time PCR amplification using iQ SYBR Green Supermix (Bio-Rad). Primers for GAPDH and ISG15 were used as previously described [30] . Primers targeting HPGD, prostaglandin H synthase (PTGS2), PGFS, prostaglandin E synthase (PTGES), acute regulatory protein (STAR), 3b-hydroxysteroid dehydrogenase enzyme (HSD3B), side-chain cleavage enzyme (CYP11A1), and peripheral benzodiazepine receptor (PBR) were designed for this experiment (Table 1 ). All primers were designed to have an annealing temperature of 618C, single-product melting curves, and consistent amplification efficiencies. Amplification was performed at 958C for 30 sec, 618C for 30 sec, and 728C for 15 sec repeated over 40 cycles. All amplicons were verified by sequencing.
Western Blot Analysis
Proteins were extracted using a radio-immunoprecipitation assay lysis buffer with PMSF (Sigma-Aldrich), sodium metavanadate (Sigma-Aldrich), and benzamidine (Sigma-Aldrich) and were quantified using the bicinchonic acid (BCA) protein assay kit (Thermo Scientific). Protein lysates (50 lg/lane) were separated by SDS-PAGE using 12-15% gels and transferred to a nitrocellulose membrane. ISG15 was detected using monoclonal ISG15 (5F10) antibody [44] at a 1:5000 dilution and a secondary goat anti-mouse IgGhorseradish peroxidase (Santa Cruz Biotech) at a 1:2000 dilution. All samples were analyzed for actin by using a 1:2000 dilution of anti-actin antibody (Santa Cruz Biotech) expression to confirm equal loading of proteins after quantification with the BCA kit. Positive bands were detected by chemiluminescence using the Amersham ECL Plus Western Blotting Detection System (GE Healthcare).
Radioimmunoassay for Progesterone
Concentrations of progesterone (ng/ml) in serum were determined in duplicate by radioimmunoassay as previously described [45] . The sensitivity of the assay was 2 pg, and the mean intra-and interassay coefficients of variation were 11% and 21%, respectively (n ¼ 3).
FIG. 2. Systemic delivery of roIFNT through either the uterine vein or the ovarian artery.
A) The anatomy of the utero-ovarian vascular system and the position of the mini-osmotic pump and catheter placement for delivery of roIFNT into the uterine vein. B) Quantitation of induction of ISG15 mRNA in the CL following acute injection of roIFNT into the ovarian artery or following 24-h infusion of roIFNT into the uterine vein using mini-osmotic pumps. Day 10 cyclic ewes received an acute ovarian arterial injection (OA) of BSA (BSA; n ¼ 2) or roIFNT (IFNT; n ¼ 2) into the ovarian artery or a 24-h infusions of BSA (BSA; n ¼ 2) or roIFNT (IFNT; n ¼ 3) into the uterine vein. Real-time PCR values (2 ÀDCt ) are presented for relative amounts of mRNA for each treatment group normalized to GAPDH. Data are presented as the mean 6 SEM with significant differences (P , 0.05) between treatments noted by different lowercase letters.
Statistical Analysis
General linear models with pregnancy status or infusion treatment as main effects were used to determine primary differences. When appropriate (P , 0.05), least-square means were separated using t-tests (pdiff option in Statistical Analysis System; SAS Institute Inc.). GAPDH was used as a housekeeping gene for real-time PCR and did not change with pregnancy status or uterine vein infusion treatment. Because GAPDH did not change across treatments, it was used to normalize each targeted mRNA amplification by using the DCt (target Ct À GAPDH Ct) values [46, 47] . Data are represented by graphing target values normalized to GAPDH using 2
ÀDCt values calculated for each group. Analyzing GAPDH as a covariate with raw Ct values for targeted genes provided similar results when compared to the DCt approach used herein. A general linear model using repeated measures was used to evaluate differences in concentrations of progesterone in serum. Data were normalized in the 24-h uterine vein infusion model for concentrations of progesterone at the time of PGF injection.
RESULTS
IFNT Is the Active Cytokine Contributing to Antiviral Activity in Uterine Vein Blood
Antiviral index was greater (P , 0.05) (Fig. 1 ) in uterine vein plasma and serum from ewes on Day 15 of pregnancy compared to the estrous cycle. Uterine vein plasma from Day 15 cyclic ewes was spiked with 500 IU/ml of roIFNT and had antiviral activity similar to uterine vein plasma from Day 15 pregnant ewes. Preadsorption of uterine vein plasma from Day 15 pregnant ewes with normal rabbit serum did not affect the antiviral index. However, preadsorption of uterine vein plasma from Day 15 pregnant ewes with antibody against roIFNT decreased (P , 0.05) antiviral activity. A similar loss in antiviral activity was observed when serum instead of plasma from Day 15 pregnant ewes was preadsorbed with antibody against roIFNT.
Development of a Method for Endocrine Delivery of roIFNT
Two endocrine methods of roIFNT delivery to activate ISGs in the CL were examined. Injection of roIFNT into the ovarian artery over 1 min increased ISG15 mRNA expression in CL 12 h later compared to BSA injection (P , 0.05). However, induction of ISG15 was greater (P , 0.05) following 24-h infusion of roIFNT, compared to BSA, into the uterine vein and when compared to acute injection of roIFNT into the ovarian artery (Fig. 2) . Because 24-h delivery of roIFNT into uterine vein elicited a greater ISG response in the CL, this method of testing endocrine effects of roIFNT was used for all subsequent studies.
ISG15 mRNA in CL, Endometrium, and Liver from Day 15 Pregnant Ewes
Concentration of ISG15 mRNA was greater (P , 0.05) in CL, and endometrium from Day 15 pregnant ewes compared to Day 15 nonpregnant ewes (Fig. 3) , but the abundance of PTGS2, PGFS, PTGES, HPGD, STAR, PBR, CYP11A1, and HSD3B mRNAs was not affected by pregnancy status (data not shown).
Infusion of roIFNT into the Uterine Vein for 24 h Induces ISG15 in the CL But Does Not Immediately Protect Against PGF-Induced Decline in mRNAs Encoding Steroidogenic Proteins
Luteal, endometrial, and liver concentrations of ISG15 mRNA were greater (P , 0.05) in ewes that received roIFNT compared to BSA controls and in ewes receiving roIFNT plus PGF versus BSA plus PGF (P , 0.05) (Fig. 3) . ISG15 and ISGylated proteins were more abundant (P , 0.05) in CL from roIFNT-treated versus BSA-treated ewes and from roIFNT plus PGF-treated versus BSA plus PGF-treated ewes (Fig. 4) .
The prostaglandin biosynthetic pathway was examined in the CL using semiquantitative real-time PCR for mRNAs encoding PGDH, PTGES, PGFS, and PTGS2. None of these mRNAs was affected by 24-h uterine vein infusion of BSA or roIFNT in the presence or absence of PGF administered at 12 h (data not shown). However, concentration of several mRNAs encoding critical steroidogenic proteins was down-regulated in CL following PGF, roIFNT, and PGF plus roIFNT treatments. For example, STAR, PBR, and HSD3B mRNA concentrations were suppressed (P , 0.05) in CL in response to PGF in BSAand roIFNT-infused ewes (Fig. 5) . Likewise, in response to roIFNT alone, the concentrations of STAR and HSDB mRNAs were diminished, but CYP11A1 mRNA concentrations were not affected by treatment.
Infusion of roIFNT into the Uterine Vein for 24 h Provides a Delayed and Marginal Protection Against PGF-Induced Decline in Serum Progesterone
Concentrations of progesterone in serum remained high and reflective of luteal-phase levels throughout the 24-h infusion of BSA and roIFNT into the uterine vein (Fig. 6) . Following injection of PGF at 12 h, BSA-infused ewes exhibited a decline (P , 0.05) in concentrations of progesterone in serum 6 h later, which remained suppressed for the next 6 h. Infusion of roIFNT did not prevent the decline (P , 0.05) in serum progesterone at 6 h following injection of PGF. However, by 8 h following treatment with PGF, serum progesterone recovered to concentrations in roIFNT-infused ewes that were not different from those for BSA-or roIFNT-infused controls. This response also was observed in roIFNT-infused ewes for 7 days during the estrous cycle. 
ENDOCRINE ACTIONS OF IFNT DURING EARLY PREGNANCY
Infusion of roIFNT into the Uterine Vein for 7 Days Extends the Luteal Phase Until Day 32 Postestrus
Mini-osmotic pumps that delivered either 200 lg of BSA or roIFNT per day for 7 days into the uterine vein were installed on Day 10 of the estrous cycle. Concentrations of serum progesterone were similar within BSA-infused ewes from Days 10-15 and then declined thereafter, indicative of luteolysis (Fig. 6) . All BSA-infused ewes had subluteal phase concentrations of progesterone in serum by Day 17 and exhibited estrus by 18.2 6 0.31 days (mean 6 SEM).
One out of five roIFNT-infused ewes exhibited estrus on Day 19. Concentrations of serum progesterone in this ewe were high on Day 10 and declined by Day 12 to less than 0.5 ng/ml, which was indicative of early onset of luteolysis compared to BSA-and roIFNT-infused contemporaries (Fig. 6) . The other four roIFNT-infused ewes had concentrations of serum progesterone that were high on Days 10-11, which then declined (P , 0.05) by Days 13-20 to concentrations that were lower but never less than 1 ng/ml. Concentrations of serum progesterone stabilized above 1 ng/ml until Day 19, then remained high (.1.5 ng/ml) through Day 32, when all of these ewes were necropsied to examine the CL. All CL marked with charcoal on Day 10 in these roIFNT-infused ewes were present as primary CL on Day 32. None of these ewes exhibited estrus before Day 32 postestrus.
DISCUSSION
Because of the strong induction of ISGs in the endometrium and the lack of reports describing significant antiviral activity in the uterine vein from pregnant ewes, it was generally thought that IFNT elicits antiluteolytic effects entirely within the uterus. However, reports of extrauterine induction of ISGs (i.e., in blood cells) during early pregnancy in ruminants [28] [29] [30] led Oliveira et al. [31] to reexamine if uterine vein blood from Day 15 pregnant ewes contains antiviral activity. Antiviral activity was present in the uterine vein of pregnant, but not nonpregnant, ewes or in blood samples from the jugular vein or uterine artery from Day 15 pregnant ewes [31] . To accurately attribute ISG expression in the CL to endocrine actions of IFNT, we confirmed in the present study that antiviral activity in uterine vein plasma and serum was caused specifically by IFNT. Exactly how IFNT is released into the uterine vein is unknown, but it might be through reduction of tight junctions in the endometrium. For example, Satterfield et al. [48] described reduced tight junctions in ovine uteri on Day 12, which would allow a permeable architecture conducive to transport of small molecules. The leaky nature of the endometrium might facilitate transport of IFNT to capillary beds and entry into venous blood leaving the uterus.
Relative amounts of ISG15 mRNA were greater in endometrium and CL, but not in liver, from Day 15 pregnant versus nonpregnant ewes. Pregnancy status had no effect on liver ISG15 mRNA concentrations. For this reason, there might be some degree of countercurrent exchange of IFNT from the uterine vein to the ovarian artery during pregnancy. Whether a local pathway of delivery of IFNT from the uterus to the ovary exists is beyond the scope of the present study. Ewes that received an acute (24-h) uterine vein infusion of roIFNT responded with greater concentrations of ISG15 mRNA in peripheral tissues including CL, endometrium, and liver. A similar increase in ISG15 mRNA was observed in CL both ipsilateral and contralateral to the side of the uterus in which the mini-osmotic pump was placed (data not shown), suggesting an endocrine effect of IFNT. The ISG response in 
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liver might reflect subtle differences in release of IFNT during pregnancy when compared to the uterine vein infusion model. For example, IFNT may be released into the uterine vein in a slightly different pattern, time (days), and concentration during pregnancy when compared to the controlled release of roIFNT in the 24-h infusion model. Also, infusion of roIFNT elicited greater concentrations of ISG15 mRNA in liver and CL, but not in endometrium, compared to Day 15 of pregnancy. Collectively, these results provide evidence that IFNT is eliciting an endocrine effect, but the possibility also exists that IFNT is transported from the uterine vein locally through utero-ovarian vascular plexus to induce ISGs in the CL ipsilateral to the uterine vein.
Silva et al. [38] reported that HPGD mRNA and enzymatic activity increased in CL from pregnant ewes on Day 13 compared to Day 4 or Day 13 of the estrous cycle. In the present experiments, relative abundance of mRNAs for PTGS2, PTGES, PGFS, and HPGD in CL collected from Day 15 nonpregnant and pregnant ewes or following 24-h infusion of roIFNT into the uterine vein of Day 10 nonpregnant ewes did not differ. Also, uterine vein infusion of roIFNT either in the presence or absence of PGF had no impact on mRNAs encoding prostaglandin synthesis or metabolism in the CL. Costine et al. [49] also reported no differences in HPGD between cyclic and pregnant ewes on Days 12-13, which is consistent with results of the present study. However, these results do not exclude the possibility that mRNAs for prostaglandin-synthesizing and -metabolizing enzymes, associated proteins, and enzymatic activities are regulated following 24-h exposure to roIFNT yet before the peak in production of PGF on Day 15.
Interferon gamma has been reported to decrease activities of both STAR and P450-SCC in various systems [50] . To our knowledge, the impact of IFNT on the CL has not been described. The mRNAs encoding STAR, PBR, HSD3B, and CYP11A1 did not differ in CL from pregnant compared to nonpregnant ewes. When examining luteal responses 12 h following PGF challenge on Day 10 of the estrous cycle, STAR, PBR, and HSD3B mRNAs were diminished, regardless of treatment with roIFNT. The acute suppression of these mRNAs in response to PGF is consistent with luteolytic and antisteroidogenic actions. Surprisingly, infusion of roIFNT for 24 h in the absence of PGF also suppressed STAR and HSD3B mRNAs. The endocrine role of IFNT on concentrations of progesterone in serum was studied following a 24-h period of infusion of roIFNT into the uterine vein. Ewes treated with BSA and roIFNT alone had similar concentrations of progesterone during the last 12 h of infusion, which remained high. Thus, 24-h infusion of roIFNT does not enhance steroidogenesis.
Doses of PGF equal to or less than 3 mg per 60 kg of body weight result in a temporary decrease in serum progesterone, whereas higher doses cause a prolonged, terminal decline in serum progesterone [51] . In the present experiments, injection of 5 mg of PGF per 60 kg of body weight elicited a decrease in serum progesterone by 6 h that was sustained for 12 h compared to BSA-or IFN-infused controls. Ewes infused with roIFNT and injected with PGF 12 h later had serum concentrations of progesterone that declined by 6 h, followed by recovery within 8 h to concentrations similar to those of control BSA-and roIFNT-treated ewes for the remainder of the experiment. The recovery of progesterone in these ewes was subtle but interpreted to reflect a deviation from luteolysis. For this reason, 7-day infusion studies were completed to test the hypothesis that longer-term infusion of roIFNT into the uterine vein would prevent a prolonged decrease in concentrations of serum progesterone in response to endogenous PGF release and extend the estrous cycle. Seven-day infusion of roIFNT into the uterine vein starting on Day 10 of the estrous cycle was selected as a model because of previous embryo transfer experiments.
Transfer of Day 5-9 embryos into uteri of cyclic ewes on Day 5 of the estrous cycle extends luteal life span [52] . If conceptuses from Day 12-13 are transferred into recipient ewes later than Day 12 postestrus, the chances of establishing and maintaining pregnancy are drastically reduced [52, 53] . Thus, the uterus is programmed to receive a pregnancy recognition signal by Day 12-that is, well before activation of luteolysis so that it can abrogate that mechanism. Hansen et al. [7] reported an interestrous interval of 19 days when conceptuses were flushed on Day 13 and an extension of this interval to 35 days when conceptuses were flushed from the pregnant uterus on Day 17. That study is interpreted to indicate that exposure to the conceptus (IFNT) is necessary until Day 17 for significant extension of the estrous cycle.
Ewes infused with BSA from Days 10 to 17 of the estrous cycle responded to endogenous PGF release with a significant decline in circulating progesterone by Day 16, which declined further (,1 ng/ml) by Day 17. All BSA-infused ewes exhibited estrus by Day 19. One roIFNT-infused ewe returned to estrus on Day 19, because luteolysis was premature and initiated shortly after insertion of the mini-osmotic pumps. This conclusion is based on a more rapid decline in serum progesterone concentrations in this ewe when compared to BSA controls. This ewe exhibited a declining pattern of serum progesterone from Day 10 to concentrations below 0.5 ng/ml by Days 11-12. Why the concentration of serum progesterone in this ewe increased after Day 12 to above 1 ng/ml by Day 16 is unknown, but it may have been caused by continued release of roIFNT from the mini-pump even in the face of premature luteolysis. The progesterone profile for this ewe might reflect two possible conditions that lead to early embryo mortality: delayed release of IFNT from the conceptus or exposure of the CL to PGF before significant release of IFNT from the conceptus.
In the present study, extension of the estrous cycle through Day 32 by infusion of 200 lg/day of roIFNT from Days 10 to 17 into the uterine vein is significant when compared to results of other studies using intrauterine or subcutaneous delivery of roIFNT. For example, intrauterine infusion of 50 lg of native IFNT twice daily extended interestrous intervals to an average of 27 days [9] , and intrauterine infusion of 340 lg of roIFNT for 8 days extended interestrous intervals from 25 to 64 days in four of five ewes [10] . Intrauterine infusion of 1.4 3 10 7 U (200 lg) per day of roIFNT from Days 10 to 18 extended interestrous intervals to an average of 33 6 14 days (mean 6 SEM) [11] .
Systemic functions of type I IFN, through intramuscular or subcutaneous injection, have been examined by several groups for capacity to extend interestrous interval as well as ability to increase fertility [54] [55] [56] [57] [58] [59] . These studies employed milligram quantities of IFN administered as twice-daily injections, induced hyperthermia, and in some cases, either had no effect or caused a decline in fertility. The concentrations of roIFNT utilized in the previous experiments were up to 20-fold greater than concentrations used in the current experiments. These roIFNT treatments administered in one or two daily injections increased rectal temperatures, respiration rates, and hyperthermia. The milligram doses of IFN were reduced to 2 3 10 7 U (200 lg) to avoid hyperthermia and high mortality of ewes [43] . Delivery of 200 lg of roIFNT over a 24-h period into the uterine vein by mini-osmotic pumps in the present study had no effect on rectal temperature and extended estrous cycles to greater than 32 days.
Subcutaneous [43] and intramuscular [14] injections of 2 mg of roIFNT between Days 11 and 17 increased ISG15 mRNA concentrations in the CL of ewes. Chen et al. [14] reported an average interestrous interval of 32.7 days in ewes that received intrauterine infusions of 200 lg of roIFNT, but an average interval of only 17 and 22 days for ewes injected i.m. with 200 lg or 2 mg of roIFNT, respectively. These investigators also described an increase in ISG15 expression in response to uterine infusion of roIFNT and subcutaneous injection of 2 mg of roIFNT, but not following injection of 200 lg of roIFNT. None of the systemic methods of roIFNT delivery induced an extended delay in return to estrus. However, both methods of roIFNT delivery induced ISGs, such as MX1, in the endometrium. In the current study, four out of five ewes treated with a 7-day infusion of roIFNT into the uterine vein maintained functional CL to necropsy on Day 32 after onset of estrus.
In conclusion, IFNT is released into the uterine vein during early pregnancy in ewes and acts in an endocrine manner to induce ISGs in the CL. Exactly how IFNT reaches the CL remains to be determined. Early studies by Moor and Rowson [52] , which were supported by experiments performed by Mapletoft et al. [60] , suggest that the conceptus releases a signal that acts locally rather than systemically. One accepted paracrine action is antiluteolytic, through altering release of PGF from the uterus. The present results are interpreted to indicate a local endocrine action of IFNT on the CL. This could occur through release of IFNT into the uterine vein and then delivery to the ovarian artery. A systemic role for IFNT in recognition of pregnancy is not supported by the Moor and Rowson [52] or the Mapletoft et al. [60] study, but uterine vein blood cells from the gravid uterine horn had similar ISGs when compared to jugular vein blood cells [31] , suggesting that IFNT is released systemically in amounts large enough to induce ISGs in blood cells, but not in amounts necessary to induce the uterine antiluteolytic response.
Short-term infusion of roIFNT into the uterine vein induces an acute decline in STAR and HSD3B mRNA concentrations in the CL. This decline in steroidogenic mediators is possibly a direct consequence of endocrine action of IFNT on the CL. It is hypothesized that in addition to well-characterized antiluteolytic effects through altering pulsatile release of PGF, IFNT may also induce cell survival mechanisms similar to a classical heat shock response so that the CL becomes resistant to future insults, such as change in pulsatility and an increase in PGF as maternal recognition of pregnancy continues. The present experiments demonstrate that delivery of roIFNT into the uterine vein causes a significant extension of the luteal phase and that osmotic release into the uterine vein better reflects physiologic exposure to roIFNT during early pregnancy when compared to other models using twice intramuscular or subcutaneous daily injections.
